KainosMed Begins Preliminary Research on COVID-19 Treatment with Pasteur Institute

[Asia Economy Reporter Hyunseok Yoo] Kainosmed, which is pursuing a merger listing with Hana Financial No.11 SPAC, announced on the 2nd that it has signed a screening contract with the Korea Pasteur Institute (IPK) to create new drugs for the treatment of coronavirus disease (COVID-19).

The Korea Pasteur Institute will verify the antiviral efficacy of compounds under Kainosmed's own research using infectious cell analysis of SARS-associated coronavirus, including COVID-19.

This is a preliminary commissioned study to confirm the possibility of developing a COVID-19 treatment. A company official said, "There is similarity in mechanism and chemical structure between Remdesivir by Gilead Sciences, which has recently attracted attention as a COVID-19 treatment, and the compounds under Kainosmed's own research, so the experimental results are expected."

Meanwhile, five research institutions including the Korea Pasteur Institute and the Korea Research Institute of Chemical Technology have decided to promote 'drug repositioning' research for the development of COVID-19 treatments. 'Drug repositioning' refers to a strategy that seeks to find whether already approved drugs or compounds researched for specific purposes have efficacy in treating other diseases.

This content was produced with the assistance of AI translation services.